This is the conclusion of a two-part series. Part 1, “Academic Publishing’s $28 Billion Business Model (Part 1),” explains how the system was built and where the money flows.

Part 1 of this series mapped the machine. Five companies now publish more than half of all peer-reviewed scientific literature.¹ Peer reviewers contributed over 100 million hours of unpaid labor in 2020. The salary-equivalent value of that time exceeded $1.5 billion in the US alone.² Elsevier’s profit margins have run above 35% for years. These margins are sustained because the core intellectual content arrives at no cost. Manuscripts and peer review are provided for free by the scientific community.³ Meanwhile, the impact factor and the h-index have wired career advancement to journal prestige. This makes unilateral exit nearly impossible for any individual researcher.

Part 2 follows the damage. We look at the library systems forced into multi-year standoffs and the researchers structurally locked out of high-cost venues. We also examine the reform movements building something new outside the publisher’s walls.

Part 6: The Library Crisis (Paying Twice for the Same Work)

University libraries are the third party caught in this system. They are squeezed from two directions. Publisher prices rise faster than inflation. Campus budgets have not kept pace.

The Serials Crisis

“Serials crisis” is the librarians’ term for a trend starting in the 1980s. Journal subscription prices rose 8 to 12% per year. These increases compounded over decades while library budgets grew at only 2 to 3%. As a result, many libraries now spend 60 to 70% of their acquisitions budgets on serials. This leaves little for books or other databases.

The literature describes journal prices tripling over a single decade. This forced librarians into an impossible cycle. They cancel journals to save money. Publishers raise prices to compensate for lost subscriptions. Remaining subscribers pay more, leading to more cancellations.⁴

The Big Deal

Publishers responded in the late 1990s with the “Big Deal.” Instead of à la carte journal subscriptions, they offered libraries comprehensive packages of their entire catalog at a bundled price. The offer looked attractive at first. Libraries gained access to thousands of journals for less than the cost of each individually.

The problems revealed themselves over time:

· Libraries gained access to thousands of journals they did not need.

· The bundling obscured per-title costs.

· Contracts locked libraries into multi-year agreements with annual price escalators of 4 to 8%.

· Canceling individual titles was often contractually prohibited.

· Non-disclosure agreements prevented libraries from sharing pricing with each other, which blocked collective bargaining.

Harvard University announced in 2012 that it could no longer afford to sustain all its journal subscriptions. The Harvard Faculty Advisory Council memo described the “take it or leave it” nature of these contracts as fiscally unsustainable and academically restrictive.

The University of California cancelled its Elsevier subscription entirely in 2019. This affected access for 10 campuses and 280,000 researchers. They reached a transformative agreement after two years of public negotiations, but the leverage required took a multi-year standoff.

What the Numbers Look Like for a Single University

MIT’s annual spend on journal subscriptions was estimated at over $6 million in the late 2010s. That figure is typical for a major research university. The Association of Research Libraries reported median library expenditures on serials exceeding $11 million annually across its member institutions in recent years.

That $11 million goes to publishers year after year. It pays for content created and reviewed largely by the same university’s faculty. This work is supported by grant funding from federal agencies like the NIH and NSF. These agencies are funded by taxpayers.

The taxpayer pays for the research. The taxpayer’s university pays to access the results. The same person’s taxes fund both ends of the transaction.

Part 7: The “Paid in Exposure” Problem

In creative fields like music or photography, the “exposure” argument is a familiar frustration. Clients claim they cannot pay, but suggest the exposure will benefit the artist’s career.

Academic publishing runs on the same logic. It has been formalized into institutional policy.

The publisher’s argument is that researchers benefit from publication through career advancement. The prestige of publishing in Nature confers tenure and grants. It leads to speaking invitations and salary increases. This career capital is the return on submitting unpaid work.

This argument is true in a narrow sense. Publication does drive academic careers. However, it inverts the relationship. The publisher captures direct cash value through subscription revenue and fees. The researcher captures indirect career value. This value is contingent on whether their paper is accepted and whether the field recognizes the journal as prestigious.

The exposure argument has another flaw. It only works for researchers at well-funded institutions who can afford to publish open access. It favors those with the institutional prestige to get papers into high-impact journals. Researchers at smaller universities or in developing countries receive the same labor extraction but far less of the career benefit.

The entire editorial board of the Journal of Informetrics resigned en masse in 2021 over Elsevier’s fees. They stated that researchers should not need to pay large fees to publish open access, particularly when the work is done by unpaid academics.

Part 8: What the Reformers Are Trying to Do

The system has many critics. Some of the alternatives are gaining real traction. The career incentive mechanisms covered in Part 1 remain the central obstacle. The impact factor and the h-index create a structural lock-in that every reform movement must face.

Preprint Servers

The arXiv server launched in 1991 for physics and mathematics. Papers are posted publicly and immediately. Peer review happens later or elsewhere. The server is maintained by Cornell University Library. It costs roughly $2 million per year to run. It is accessed millions of times daily by researchers worldwide.

Biology followed with bioRxiv in 2013. Medicine followed with medRxiv in 2019. A 2019 analysis in eLife tracked over 37,000 bioRxiv preprints and found rapid adoption. Papers posted to bioRxiv were downloaded an average of 518 times within six months of posting.⁵ During the COVID-19 pandemic, medRxiv posted thousands of preprints within days of submission. The traditional peer review timeline of 3 to 18 months became clinically irrelevant as the world needed data in real time.

The preprint model separates dissemination from certification. The paper is public immediately. Peer review happens alongside or after the release.

Plan S and Funder Mandates

Plan S launched in 2018. It required that research funded by participating European agencies be published in full open access journals immediately. A growing number of funders globally have adopted similar policies.

The US government went further in 2022. The White House Office of Science and Technology Policy (OSTP) mandated that all federally funded research in the US must be freely accessible immediately upon publication. This rule takes effect in 2025. It is the most significant open access policy shift in US history.

Publishers responded by pivoting further into author fees. They essentially transformed subscription income into author-side income. The net effect on their profit margins has been minimal.

Diamond Open Access

“Diamond” open access is the alternative that removes publishers. These journals are free to read and free to publish in. They are funded by libraries or universities directly. The Journal of Machine Learning Research and thousands of society journals operate on this model.

The financial comparison is striking. arXiv runs for $2 million a year. Traditional journal hosting costs for a well-run operation are estimated at $200 to $1,000 per article. The gap between what is technologically necessary and what publishers charge is the margin.

The DeSci Movement

Decentralized Science (DeSci) is the most radical proposal. It uses blockchain and decentralized autonomous organizations (DAOs) to rebuild scientific publishing outside the legacy infrastructure.⁸

A 2022 paper in IEEE Transactions on Computational Social Systems by Ding and colleagues described the vision. DeSci changes the basic structure of current scientific systems. It reshapes the cooperation mode and the incentive mechanism.⁶

In practice, DeSci proposals include: * On-chain peer review: Reviewer contributions are recorded on a public blockchain. This creates a transparent record of service that can be cited or compensated. * NFT-based IP ownership: Researchers retain tokenized ownership of their work. * DAO-governed journals: Editorial decisions are made by communities of token holders rather than publisher employees. * Funding DAOs: Capital is distributed directly to researchers via community voting.

Projects like Molecule and VitaDAO are operational experiments. The technology works at a small scale. Adoption is the main challenge.⁷ Evaluation of scientific careers must decouple from journal names for these platforms to succeed.

The San Francisco Declaration on Research Assessment (DORA)

DORA commits signatories to not using journal impact factor as a surrogate for quality. It aims to stop the use of metrics in hiring and promotion decisions. Over 23,000 individuals and 2,500 organizations have signed as of 2024. The signal is clear, even if practice is slow to follow.

Figure 1: The Publish-or-Perish Feedback Loop. The self-reinforcing cycle that locks academic publishing in place. Researchers must publish in high-IF journals to advance careers. Publishers set the criteria for prestige. Universities pay fees to maintain access. Federal funding supports the researchers producing the content. Each arrow represents a dependency that makes unilateral exit nearly impossible. © MolecularWeights.com

Part 9: The Humanities vs. The Sciences

Publishing economics are sharpest in STEM fields, but the humanities have their own version of the problem. In some ways, their crisis is worse.

Sciences: The APC Burden

In the natural sciences and medicine, the primary cost is the author fee (APC). A chemistry research group publishing 10 papers per year can spend $60,000 to $150,000 on these fees alone. This line item competes directly with salary and equipment budgets. Early-career researchers without large grants often cannot afford high-impact fees at all. This structurally disadvantages them relative to well-funded labs.

Humanities: The Monograph Crisis

In the humanities, prestige hinges on the peer-reviewed monograph (book). A tenure case often requires a book published by a prestigious university press.

University presses are nonprofits. They have been squeezed by the same library budget cuts that hit journal publishers. However, they cannot raise prices the same way commercial publishers do. The result is that university presses publish fewer books. Academic books routinely sell only 200 to 400 copies at prices of $100 or more.

The library budget cut becomes self-reinforcing. Libraries cannot afford books, so presses sell fewer. Presses become less viable and publish less. Humanities scholars then struggle to establish tenure cases.

Different Fields, Same Extraction Logic

The table below shows how publishing economics vary across fields:

Table 1: Publishing economics across academic disciplines. Left color stripe indicates APC cost burden: red = very high, orange = high, yellow = medium, green = low or free. Computer Science is a structural outlier. Conference preprints on arXiv make most CS research freely accessible at near-zero APC cost. © MolecularWeights.com

Part 10: Can This Change?

Change will likely be slow. It will require sustained external pressure.

The lock-in is structural. Researchers need journal publications. Journals need prestigious reputations. Reputation accrues over decades. Starting a new journal means starting a prestige clock from zero. No junior researcher can afford to publish in a venue with no prestige.

What Is Actually Working

Preprints have normalized sharing before peer review in many fields. The norm is not universal, but it is growing.

Funder mandates are the most powerful lever. The US OSTP mandate and European Plan S cover hundreds of thousands of papers. Publishers will adapt, but they will try to preserve revenue through author fees or new agreements.

Mass journal resignations happen periodically. When an entire editorial board defects and starts a competing open-access journal, the publisher loses both content and legitimacy.

Subscribe-to-Open (S2O) is an emerging model. Libraries pay their usual subscription fee, and the publisher makes all content open access as a result.

What Would Actually Fix It

Hiring and tenure committees must evaluate the work itself rather than the journal. If the evaluation of careers decouples from journal prestige, the leverage publishers hold collapses.

Peer review should be visible and compensated. If reviewer contributions were credited and recognized, the free labor that underpins publisher profitability would have a cost.

Funding should support diamond OA infrastructure. The technology to run high-quality publication costs a fraction of what universities currently pay. The money is already there, but it flows to shareholders instead of infrastructure.

Conclusion: The System Works, and That Is the Problem

The academic publishing system is a genuinely impressive piece of organizational design. The historical process that produced it managed to build a structure where the same labor that creates the product also validates it. The people doing that labor cannot opt out because their careers depend on the prestige that flows from the journals extracting their work.

It is not malicious. Scientists are doing work they care about. The publishers are not cartoonish villains. They run real businesses that provide genuine services. However, the incentive structure and the profit margins are hard to justify. Most underlying research was funded by the public, yet the public cannot read the results without paying a fee.

Pressure is real and growing. Preprints, funder mandates, and campus resistance are all making cracks in the walls. The scientific record belongs to science. Getting it back may take as long as building the system that captured it.

Did You Know?

· The University of California’s 10-campus system cancelled its Elsevier subscription entirely in 2019. This move would have been unthinkable a decade earlier.

· In computer science, the top venues are conferences rather than journals. Nearly all papers go onto arXiv for free on the day they are submitted. An entire field’s prestige structure can be built on open access.

· “Predatory journals” now number in the tens of thousands. They charge author fees and perform no real peer review. They exist because the pressure to publish is intense enough that some researchers will pay to avoid scrutiny.

References

1. Larivière V, Haustein S, Mongeon P (2015). The oligopoly of academic publishers in the digital era. PLOS ONE 10(6):e0127502. doi:10.1371/journal.pone.0127502

2. Aczél B, Szaszi B, Holcombe AO (2021). A billion-dollar donation: estimating the cost of researchers’ time spent on peer review. Research Integrity and Peer Review 6:14. doi:10.1186/s41073-021-00118-2

3. RELX Group (2022). Annual Report and Financial Statements 2022. relx.com

4. Bergstrom CT, Bergstrom TC (2004). The costs and benefits of library site licenses to academic journals. PNAS 101(3):897-902. doi:10.1073/pnas.0305628101

5. Abdill RJ, Blekhman R (2019). Tracking the popularity and outcomes of all bioRxiv preprints. eLife 8:e45133. doi:10.7554/eLife.45133

6. Ding W, Hou J, Li J, Guo C, Qin J, Kozma R, Wang FY (2022). DeSci based on Web3 and DAO: A comprehensive overview and reference model. IEEE Transactions on Computational Social Systems 9(5):1563–1573. doi:10.1109/TCSS.2022.3204745

7. Tenorio-Fornés A, Pérez Tirador E, Sánchez-Ruiz AA, Hassan S (2021). Decentralizing science: Towards an interoperable open peer review ecosystem using blockchain. Information Processing & Management 58(6):102724. doi:10.1016/j.ipm.2021.102724

8. Weidener L, Spreckelsen C (2024). Decentralized science (DeSci): definition, shared values, and guiding principles. Frontiers in Blockchain 7:1375763. doi:10.3389/fbloc.2024.1375763

The researchers write the papers. Other researchers review them for free. Universities pay billions to read them. And the publishers, who created none of it, pocket margins that make Apple look modest.

Imagine a platform where millions of highly educated professionals produce all the content, perform all the quality control, and then pay to distribute their work. A handful of corporations collect the money from both ends and share none of it with anyone. Now imagine that those professionals have no real choice in the matter, because their entire career depends on continuing to feed the machine.

This is not a hypothetical. It is the business model of academic publishing, and it has been running without serious interruption since the 1970s.

Part 1: The Machine (Who Does What, Who Gets Paid)

To understand why this system is extraordinary, you first need a map of who does what.

The researchers (authors) conduct the science, typically paid by universities, government grants, or research institutes, almost all of which are funded by taxpayers. They write the paper, usually over months or years. They format it to a journal’s specific requirements. They revise it after peer review. They sign over copyright to the publisher. They receive no payment from the journal.

The peer reviewers are other researchers (usually two to four per paper) who read the manuscript, check the methods, challenge the conclusions, and write detailed critiques. This takes an average of 5–8 hours per review. They receive no payment from the journal. (A handful of journals offer token honoraria of $50–$100, which amounts to $6–$20/hour for expert-level scientific evaluation.)

The editors at most commercial journals are either unpaid academic volunteers serving as handling editors, or in the case of senior editors at high-prestige journals, salaried employees of the publisher. At society-run journals, editors are typically academics receiving modest stipends or none. The substantive intellectual gatekeeping (deciding what is and isn’t worth reviewing) is done largely by unpaid academic labor.

The publisher handles layout, digital hosting, DOI assignment, and metadata management. It runs the submission platform, employs a sales force to negotiate institutional subscriptions, and lobbies funders and governments on policy questions.

The university library pays the publisher an annual subscription fee, ranging from thousands to tens of millions of dollars depending on the package, so that its faculty and students can read the content those same faculty helped produce.

The reader outside a university who wants to read a single paper pays $30–$50 per article, or is locked out entirely.

The money flows from all three directions toward the publisher. None of it reaches the people who did the work.

Figure 1. The academic publishing ecosystem showing who produces each form of value (orange = unpaid academic labor), who pays (blue = funding flows), and who captures revenue (green = publisher). Taxpayer-funded research generates the raw content; peer reviewers and editors provide quality control at no cost to publishers; universities pay again for subscription access. The publisher sits at the center of all three flows.

Part 2: The Numbers Are Staggering

The sums involved are not modest.

The Big Five and Their Margins

Five companies (Elsevier, Springer Nature, Wiley, Taylor & Francis, and Sage) publish more than 50% of all peer-reviewed scientific literature globally. In 1973 their combined share was about 20%. By 2013, that figure had grown to over 50%, and the concentration has continued since.¹

The profit margins are remarkable:

Table 1. Net profit margins for the Big Five academic publishers compared with Apple, Netflix, and the S&P 500 average

For context: the pharmaceutical industry, frequently cited as a high-margin sector, averages around 15–20% net margins. The average S&P 500 company earns about 12%. Elsevier’s 37% margin has been sustained for years, described in the company’s own annual reports and independently confirmed by multiple analyses.^2,3

A 2019 analysis in Science noted: “The big three — Elsevier, Springer Nature, and Wiley — made US$3.2, US$1.9, and US$1.7 billion in revenue in 2017, respectively, with Elsevier banking 37% of revenue as profit.”³

These profits come from two revenue streams: subscription fees charged to libraries and, increasingly, article processing charges (APCs) paid by authors for open access publication.

The APC Gold Rush

A 2023 study in Quantitative Science Studies by Leigh-Ann Butler and colleagues estimated that globally, authors paid $1.06 billion in article processing charges to the Big Five publishers between 2015 and 2018 alone. That was before APC prices began accelerating.⁴

Table 2. Total open-access article processing charge (APC) revenue collected by the Big Five publishers, 2015-2018. Gold OA = author pays APC; Green OA = free after embargo

“Hybrid” OA means the journal still charges libraries a subscription and charges authors an APC to make their specific paper free, sometimes called “double dipping.” The publishers collect from both ends simultaneously.

What Do APCs Actually Cost?

Here are current (2024–2025) APC fees at major journals, mostly in the hard sciences:

Table 3. Open-access article processing charges (APCs) at major hard-science journals, 2024-2025. Orange bars = for-profit publishers; blue bars = nonprofit/society publishers. *eLife moved to a “publish then review” model in 2023, charging $3,000 regardless of final decision.

The Lancet’s APC of $10,600 to publish a single paper publicly carries a steep cost. A postdoctoral researcher’s annual salary at many US institutions is around $55,000–$65,000. Publishing one open-access paper in that journal costs roughly 15–20% of their annual salary, paid to the publisher rather than to the researcher.

In fields like chemistry and physics where multiple papers per year is expected, the cumulative APC burden on grant budgets is substantial.

APC Inflation Is Outrunning General Inflation

A 2019 analysis in LIBER Quarterly by Khoo found that increases in APCs were proceeding at three times the rate that would be expected if APCs tracked general inflation.⁵ This mirrors the earlier serials crisis, where subscription costs rose at 8–12% annually even as library budgets stagnated or shrank.

The open-access “solution” that publishers embraced was not really a solution. It was a migration of the same extraction logic from libraries to grant budgets.

Part 3: The Peer Review Economy (100 Million Free Hours)

The intellectual beating heart of academic publishing is peer review: the process by which other scientists evaluate a manuscript before it is published. Without this labor, journals would have nothing to sell.

A landmark 2021 study in Research Integrity and Peer Review by Aczél and colleagues made the hidden economy of peer review visible for the first time at scale.⁶

Across approximately 1.7 million papers published in 2020, they estimated:

Total peer review hours globally: over 100 million

That is equivalent to over 15,000 person-years of full-time labor

Estimated monetary value of US-based reviewer time: $1.5 billion USD

China-based reviewers: $600 million USD

UK-based reviewers: close to $400 million USD

The authors note their estimates are “very likely to be under-estimates” because they reflect only a portion of all journals worldwide.

None of this labor is compensated by publishers. The $2.5+ billion in reviewer labor value in the US, China, and UK alone (performed in a single year) flows into the publisher’s product at zero cost.

“The numbers highlight the enormous amount of work and time that researchers provide to the publication system,” Aczél et al. write, “and the importance of considering alternative ways of structuring, and paying for, peer review.”⁶

The analogy to content creation is apt here. YouTube does not pay for the videos people watch; creators do. But YouTube shares advertising revenue with creators. Twitch pays streamers. Academic publishers extract peer review labor, derive direct commercial value from it, and pay nothing in return.

Figure 2. Elsevier’s 36–37% profit margin sits above Apple, Google, major pharmaceutical companies, and Netflix. These margins are sustained partly because the core intellectual content (manuscripts, peer review, editorial decisions) is provided at no cost by publicly funded academics. Sources: RELX Group annual reports; Eddy 2019 (Science); Larivière et al. 2015 (PLOS ONE).

Part 4: The Impact Factor, A Metric That Ate Science

To understand why researchers continue feeding a system that extracts so much from them, you need to understand the impact factor, the single number that controls academic careers more than any hiring committee, grant panel, or peer assessment.

What It Is

The impact factor (IF) for a given journal is calculated annually by Clarivate (formerly Thomson Reuters). It equals the number of citations received in the current year to papers published in that journal in the previous two years, divided by the number of citable papers published in those two years.

A journal with an IF of 10.0 means that, on average, each paper it published over the past two years received 10 citations in the current year.

The concept was created by information scientist Eugene Garfield in the 1950s as a tool to help librarians identify which journals were being cited most, a collection management tool, not a research quality metric. As a 2025 editorial in the BMJ put it: “The impact factor was originally intended by Garfield to be a tracking device and a retrieval tool… However, since then it has been repeatedly used to assess the quality of authors’ research, particularly for purposes of funding and awarding tenure, against Garfield’s advice that this was not a legitimate use.”⁷

How It Warped Science

When the IF became the proxy for scientific quality, it created incentives that now define research careers:

Publish in high-IF journals above all else. A paper in Nature (IF ~65) counts far more toward promotion than three papers in solid specialty journals with IFs of 3–5, regardless of actual scientific impact.

Chasing the hot topic. Work likely to generate quick citations because it is trendy, controversial, or broadly applicable, gets preferred over careful, foundational work.

Review inflation. Studies have documented systematic gaming of IF through citation cartels, coercive self-citation requests from editors, and strategic citation practices within research communities.⁸

Journal stacking. Publishers bundle less-cited journals with high-IF journals in subscription packages, effectively using the prestige of a few to subsidize the rest.

Predatory journals. The IF system created demand for publication slots at any cost, and an entire industry of fake or low-quality journals (“predatory journals”) emerged to satisfy it, charging APCs and performing little or no real peer review. Estimates suggest over 10,000 predatory journals now exist.

The Numbers Publishers Don’t Advertise

The IF of a journal is heavily skewed by a few highly cited papers. In most journals, the majority of papers are cited fewer times than the journal’s IF, because a small number of landmark papers inflate the mean.

Review articles and methods papers attract disproportionate citations; primary research papers often don’t. A journal can boost its IF by publishing more review articles.

The IF window is two years, too short to capture fields where citation takes longer (mathematics, geoscience, parts of physics).

Humanities vs. sciences: This disparity is enormous. Nature’s IF of ~65 exists because biomedical papers generate rapid citations. A top philosophy journal might have an IF of 1–3, not because the work is less valuable, but because the citation culture and timescales differ completely. Applying IF comparisons across disciplines is methodologically indefensible, yet it happens constantly in hiring and promotion decisions.

Discipline Comparison: Impact Factors Across Fields

Table 4. Journal impact factors for representative top journals across ten disciplines (2023). Color coding reflects IF quartile within each discipline

A history professor and a biochemist whose departments use raw IF for promotion are being measured with instruments calibrated for different purposes entirely. The biochemist has a structural advantage that has nothing to do with the quality of their scholarship.

Part 5: Publish or Perish (The Career Machine That Feeds the Publishers)

The impact factor would not matter so much if it were not wired directly to the one thing every academic needs: their job.

The Promotion Clock

At a research university, the typical academic career path runs:

PhD (4–7 years): produce publications to get postdoc positions

Postdoc(s) (2–6 years): produce publications to get faculty positions

Assistant Professor (6 years): produce publications to get tenure

Tenure review: committee evaluates publication record: How many papers? In which journals? How often cited?

Tenured Associate Professor: produce publications for promotion to Full Professor

Full Professor: produce publications to maintain grants

At every stage, the metrics that gatekeepers use are publication-based: total papers, journal IFs, h-index (a measure combining publication count and citations), citation counts. These are the currency of academic careers.

A 2025 paper in PNAS by Trueblood and colleagues described the dynamic precisely: “Commercial publishing companies have capitalized on the centrality of publishing to the scientific enterprises of knowledge dissemination and academic recognition to extract large profits from academia by leveraging unpaid services from reviewers, creating financial barriers to research dissemination, and imposing substantial fees for open access.”⁹

Grant Funding Is Also Tied to Publication Metrics

In the US, National Institutes of Health (NIH) study sections reviewing grant applications explicitly evaluate the PI’s publication record. The National Science Foundation does similarly. In the UK, the Research Excellence Framework (REF), the national evaluation process that distributes government research funding to universities, scores universities partly on the publication output and journal prestige of their researchers.

The result: universities need their researchers to publish in prestigious journals, so universities need access to prestigious journals, so universities pay publisher subscription fees. The same institution simultaneously produces the content and pays to access it.

The h-Index and the Gamification of Careers

The h-index, introduced by physicist Jorge Hirsch in 2005, attempts to capture both productivity and citation impact in one number: a researcher has h-index n if they have published at least n papers each cited at least n times. A researcher with h = 40 has published at least 40 papers each cited at least 40 times.

Like the impact factor, the h-index was introduced as a useful summary statistic. Like the impact factor, it became a career determinant. And like the impact factor, it has well-documented problems:

It accrues monotonically: it can never decrease, even if your recent work is poor

It is strongly correlated with career age (older researchers always outperform younger ones)

It is entirely field-dependent (an h-index of 15 is outstanding in mathematics; mediocre in molecular biology)

It rewards breadth of output over depth of contribution

It can be gamed through self-citation and citation networks

Publishers did not invent the h-index, but they benefit from the culture it sustains, because that culture demands ever-increasing publication output, which fills journal pages, which generates subscription revenue and APCs.

Figure 3. Article processing charges (APCs) at major journals grouped by publisher. Hard-science journals at Springer Nature command the highest fees ($11,990 at Nature). Nonprofit publishers (PLOS, APS) charge substantially less for comparable or greater citation impact. APC inflation has run at approximately 3× the rate of general inflation since 2015 (Khoo, 2019, LIBER Quarterly).

Part 1 ends here. The machine is built, the incentives are locked, and the career penalties for non-compliance are real. But who actually gets hurt when the system runs? Part 2 of this series follows the money further: the library systems pushed to cancellation, the researchers in smaller institutions or developing countries who can’t afford APCs at all, and the reform movements that have spent decades trying to build alternatives. Preprints, funder mandates, diamond open access, blockchain-based peer review — all of them face the same structural obstacle. Part 2 asks whether any of them can move fast enough to matter.

Did You Know?

• The entire arXiv preprint server, used by millions of physicists, mathematicians, and computer scientists every day, costs roughly $2 million per year to operate. Elsevier’s annual revenue exceeds that figure by a factor of over 1,500.

• Peer reviewers collectively contributed over 100 million hours of labor to academic publishers in 2020 alone. The salary-equivalent value of US-based reviewer time in that single year exceeded $1.5 billion.⁶

• Eugene Garfield, who created the impact factor in the 1950s, explicitly warned that it should not be used to evaluate individual researchers or papers. It was designed as a library collection tool. Hiring committees have disregarded that warning for five decades.⁷

• A single paper in The Lancet costs $10,600 to publish open access. The median annual salary of a postdoctoral researcher in the US is approximately $55,000. The APC is roughly 20% of their pre-tax annual income.

References

1. Larivière V, Haustein S, Mongeon P (2015). The oligopoly of academic publishers in the digital era. PLOS ONE 10(6):e0127502. doi:10.1371/journal.pone.0127502

2. RELX Group (2022). Annual Report and Financial Statements 2022. Available at relx.com/investors/annual-reports (Elsevier operates as the Scientific, Technical & Medical division of RELX Group.)

3. Eddy T (2019). Plan S: Motivations of for-profit publishers. Science 363(6425):350. Google Scholar

4. Butler L-A, Matthias L, Simard M-A, Mongeon P, Haustein S (2023). The oligopoly’s shift to open access: How the big five academic publishers profit from article processing charges. Quantitative Science Studies 4(4):1181-1204. doi:10.1162/qss_a_00272

5. Khoo SY-S (2019). Article processing charge hyperinflation and price insensitivity: An open access sequel to the serials crisis. LIBER Quarterly 29(1):1-18. doi:10.18352/lq.10280

6. Aczél B, Kovacs M, van der Lippe T, Szaszi B (2021). A billion-dollar donation: estimating the cost of researchers’ time spent on peer review. Research Integrity and Peer Review 6:14. doi:10.1186/s41073-021-00118-2

7. Aronson J (2025). When I use a word… Academic publishing: the impact factor. BMJ 388:q2801. doi:10.1136/bmj.q2801

8. Juyal D, Thawani V, Thaledi S (2019). Impact factor: Mutation, manipulation, and distortion. Journal of Family Medicine and Primary Care 8(5):1492-1494. Google Scholar

9. Trueblood JS et al. (2025). The misalignment of incentives in academic publishing and implications for journal reform. PNAS 122(5):e2401231121. PMID 39869806

In 1992, a biochemist named John Eng at the Veterans Administration Medical Center in the Bronx was running a chemical screen through Gila monster venom. He was not looking for a diabetes drug. He was running a systematic search for histidine-terminal peptides in animal secretions — the kind of methodical work that rarely makes headlines. What he found was a 39-amino acid molecule he named exendin-4, secreted from glands along the lower jaw of Heloderma suspectum, the only venomous lizard native to the United States.¹

Eng’s paper, published in the Journal of Biological Chemistry, noted something strange: exendin-4 shared 53% of its amino acid sequence with a human gut hormone called glucagon-like peptide-1 (GLP-1), which had been characterized just a few years earlier.² It appeared to bind the same receptor. The paper closed with a careful prediction: there likely existed “an endogenous mammalian analog to the exendin peptides.”

He was describing GLP-1 without knowing it had already been found.

The 2-Minute Problem

GLP-1 is a 30-amino acid incretin hormone, made by L-cells lining the distal small intestine.³ Within minutes of eating, nutrients arriving in the gut trigger a burst of GLP-1 release. The peptide spreads into the circulation and does five things nearly simultaneously: it drives insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and sends satiety signals to the hypothalamus and brainstem, telling the brain the meal is enough.⁴ This coordination accounts for roughly 50–70% of the insulin response to an oral meal in healthy people, a phenomenon called the incretin effect.⁵

The problem is that GLP-1 lasts about 2 minutes in the bloodstream.⁶

An enzyme called DPP-4 circulates in the blood and cleaves the peptide almost immediately after it is released, cutting between the second and third amino acids and rendering it biologically inactive. Native GLP-1 was recognized as a potential drug target by the late 1980s. But infusing a molecule that disappears in 2 minutes is not practical medicine.

Figure 1. GLP-1 Signaling Cascade. After a meal, nutrients in the small intestine trigger L-cells to release GLP-1 into the bloodstream. The hormone acts simultaneously on the brain (satiety), pancreas (insulin release, glucagon suppression), and stomach (slowed emptying). DPP-4 enzyme cleaves GLP-1 with a half-life of approximately 2 minutes, which is why early drug development focused on DPP-4 inhibitors and on engineering longer-lived GLP-1 analogs.

The Lizard’s Advantage

Exendin-4 has one small but critical difference from human GLP-1: its second amino acid is glycine rather than alanine. That substitution blocks DPP-4 from cleaving it. Where human GLP-1 disappears in 2 minutes, exendin-4 persists for about 2.4 hours.⁷

In 1993, a German laboratory confirmed what Eng’s paper had implied: exendin-4 was not merely structurally similar to GLP-1 — it was a high-potency agonist at the human GLP-1 receptor, stimulating the same cAMP signaling cascade in insulin-secreting beta cells and amplifying glucose-induced insulin secretion.⁸ The Gila monster had been running the same pharmacological experiment on its own digestive biology, across evolutionary time, that pharmacologists were trying to replicate in the lab.

Pharmaceutical companies were largely uninterested. Peptide drugs in the early 1990s were considered impractical. Even exendin-4’s improved 2.4-hour half-life meant twice-daily injections at best. Eng’s work sat largely dormant for nearly a decade, until animal studies around 1999 showed the lizard peptide improved glucose tolerance, expanded beta cell mass, and reduced food intake in rodents.⁹

A synthetic version of exendin-4, called exenatide (brand name Byetta), became the first GLP-1 receptor agonist approved by the FDA on April 28, 2005.¹⁰

Engineering for a Longer Life

Twice-daily injection was never going to be a mass-market product. The next question was how to keep a peptide alive in the bloodstream long enough to work with less frequent dosing.

Figure 2. From Lizard Venom to Billion-Dollar Drug: 30 Years of GLP-1. Thirty-year arc from Gila monster venom to a global obesity drug class. Timeline is not to proportional scale. Colors denote development generation: gray = foundational pharmacology; blue = first-generation GLP-1 receptor agonists; green = semaglutide era; orange = dual GLP-1/GIP agonists and cardiovascular outcomes. Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonist; GIP, glucose-dependent insulinotropic polypeptide; MACE, major adverse cardiovascular events.

The answer came from Novo Nordisk, who engineered liraglutide (Victoza, FDA approved January 2010) by attaching a C16 fatty acid chain to a modified GLP-1 backbone. The chain binds serum albumin in the blood. Albumin is a large protein the kidneys don’t filter; drugs that hitchhike on it stay in circulation far longer. Liraglutide’s half-life extended to 13 hours — long enough for once-daily injection.¹¹

Semaglutide, whose chemistry Novo Nordisk published in 2015 and which received FDA approval in December 2017 as Ozempic for type 2 diabetes, pushed the concept further. The team made three simultaneous changes to the GLP-1 backbone: a position-8 amino acid substitution to block DPP-4 cleavage, an arginine substitution to prevent fatty-chain attachment at the wrong lysine, and attachment of a C18 fatty diacid chain via a short PEG linker at lysine-26.¹² The fatty diacid binds albumin far more tightly than liraglutide’s monoacid. The result: a plasma half-life of approximately 7 days.¹³ Once-weekly injection. Steady state in four weeks.

One molecule. Three modifications. Seven days.

What the Numbers Look Like

The STEP 1 clinical trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and no diabetes. After 68 weeks on semaglutide 2.4 mg weekly, participants lost an average of 14.9% of their body weight versus 2.4% on placebo. More than half the semaglutide group lost at least 15%.¹⁴ The two-year STEP 5 trial showed the losses were maintained: −15.2% at 104 weeks.¹⁵

Figure 3. GLP-1 Drugs Are Closing In on Surgery. Mean body-weight loss from each drug’s pivotal Phase 3 trial (SCALE for liraglutide 3.0 mg; STEP 1 for semaglutide 2.4 mg; SURMOUNT-1 for tirzepatide 15 mg). Bariatric sleeve gastrectomy shown as surgical benchmark. Trials used different populations and follow-up lengths; not head-to-head comparisons.

The cardiovascular data were even more striking. The SELECT trial, reported in the New England Journal of Medicine in 2023, followed 17,604 adults with obesity and pre-existing cardiovascular disease but no diabetes. Those on semaglutide 2.4 mg weekly had a 20% lower relative risk of major cardiovascular events, including heart attack and stroke, over a median follow-up of nearly 40 months.¹⁶ The effect was large enough to matter clinically, not just statistically. Readers familiar with how cholesterol research reshaped cardiovascular medicine over decades will recognize the significance of a single drug moving MACE outcomes by that margin.

Then came tirzepatide, from Eli Lilly. It agonizes two receptors simultaneously: GLP-1 and GIP, the other major incretin hormone. In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.4% of their body weight at 72 weeks — numbers that approach what bariatric surgery achieves.¹⁷ Why the dual agonist outperforms the single one is still being resolved.¹⁸

The Part Nobody Likes Talking About

Stop taking semaglutide, and the weight returns.

This is not a failure of willpower. The biology predicts it. In the STEP 1 extension study, participants who stopped semaglutide after 68 weeks regained roughly two-thirds of their lost weight within a year.¹⁹ In the STEP 4 withdrawal trial, patients who stopped at week 20 gained back nearly 7% of their body weight over the next 48 weeks, while those who continued the drug kept losing.²⁰

Figure 4. Stop the Drug, Regain the Weight. STEP 1 extension trial (Wilding et al., NEJM 2022). Participants who stopped semaglutide at week 68 (orange) regained most of their lost weight within a year — net loss shrank from −17.3% to −5.6% by week 120. Those who continued (blue) maintained −17.4% through week 120. Shaded region shows the widening gap.

What GLP-1 receptor agonists do, in plain terms, is supply pharmacologically the satiety signal the body was not producing effectively enough on its own. When the drug stops, the signal stops. A 2024 paper in Science used optogenetics and human fMRI to identify GLP-1 receptor neurons in the dorsomedial hypothalamus as the substrate for the preingestive satiation these drugs produce — the sense of fullness before you finish eating.²¹ When you stop the drug, those neurons go quiet, and the old appetite returns.

These are chronic medications. That framing matters enormously for insurance coverage, for public health budgets, and for whether the people who need them most will ever actually have access to them.

💡 Did You Know?

• The Gila monster eats only 3–4 times a year. Exendin-4 likely evolved to slow digestion after one of those rare, enormous meals — which is why it mimics a satiety hormone so precisely. The lizard was solving the same problem pharmacologists spent decades trying to crack.

• DPP-4 destroys roughly half of all GLP-1 before it ever reaches the bloodstream. The enzyme doesn’t wait for the hormone to circulate — it cleaves GLP-1 in the gut wall and portal vein on the way to the heart. The 2-minute half-life cited in the body of this article is what survives that first pass.

• Semaglutide is just three chemical changes away from the native GLP-1 molecule. One amino acid swap at position 8 blocks DPP-4 cleavage. One arginine swap redirects fatty-chain attachment. One C18 fatty diacid chain anchors the whole thing to albumin. That’s the difference between a 2-minute molecule and a 7-day drug.

• An oral version of semaglutide already exists. Rybelsus (approved 2019) pairs semaglutide with SNAC — a carrier molecule that briefly permeabilizes the stomach lining to let the peptide through. Getting a protein drug through the stomach without being digested was considered essentially impossible for most of the 20th century.

• GLP-1 receptors sit in the heart muscle itself. The 20% reduction in cardiovascular events seen in the SELECT trial may not be entirely explained by weight loss. Direct anti-inflammatory effects on cardiac tissue are under active investigation — and may turn out to be part of why these drugs work so well.

• The incretin effect accounts for 50–70% of your entire insulin response to a meal. In type 2 diabetes, that gut-hormone-to-pancreas signal is largely broken. GLP-1 receptor agonists don’t fix the broken signaling — they bypass it entirely by flooding the receptor pharmacologically.

An Unexpected Signal

GLP-1 receptors are not only in the pancreas and gut. They are distributed through the hypothalamus, the brainstem, and the nucleus accumbens — a region central to reward and craving.²² Animal studies have shown GLP-1 agonists reduce consumption of alcohol, cocaine, amphetamine, and nicotine in rodents.²³ Early clinical trials suggest similar signals in humans: a 2024 systematic review of five randomized trials found three showing significant reductions in alcohol and nicotine use with GLP-1 agonists.²⁴

The picture is preliminary. As addiction researcher Lorenzo Leggio summarized in Nature Medicine in 2023: “promising but unproven.”²⁵ Semaglutide-specific randomized trials for alcohol use disorder are underway but have not yet reported their primary outcomes. This may be the next chapter of the story, or it may not hold up at scale.

Either way, the trajectory since 1992 has a shape worth noting. John Eng ran a chemical screen through the venom of a Sonoran Desert lizard, found a molecule he described precisely but couldn’t explain, and his careful final sentence — predicting the mammalian analog — pointed at a hormone whose therapeutic consequences we are still mapping thirty years on.

The biology was there all along. It took a lizard to show it to us.

References

1. Eng J et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267(11):7402–7405. PMID 1313797

2. Göke R et al. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268(26):19650–19655. PMID 8396143

3. Tian L et al. (2016). The incretin hormone GLP-1 and mechanisms underlying its secretion. J Diabetes 8(6):753–775. doi:10.1111/1753-0407.12398

4. Lee YS & Jun HS (2014). Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 63(1):9–19. doi:10.1016/j.metabol.2013.08.003

5. Nauck MA et al. (2018). Incretin hormones: Their role in health and disease. Diabetes Obes Metab 20(Suppl 1):5–21. PMID 29364588

6. Nauck MA et al. (2019). GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Eur J Endocrinol 181(3):R211–R234. doi:10.1530/EJE-19-0167

7. Eng J et al. (1992) — see ref. 1. Exendin-4 DPP-4 resistance due to Gly at position 2; half-life ~2.4 h confirmed in pharmacological studies.

8. Göke R et al. (1993) — see ref. 2.

9. Nauck MA et al. (2020). GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 46:101102. doi:10.1016/j.molmet.2020.101102

10. Nauck MA et al. (2020) — see ref. 9.

11. Knudsen LB & Lau J (2019). The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol 10:155. doi:10.3389/fendo.2019.00155

12. Lau J et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 58(18):7370–7380. PMID 26308095

13. Hall SF et al. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Semaglutide. Clin Pharmacokinet 57(10):1313–1328. doi:10.1007/s40262-017-0618-7

14. Wilding JHH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 384:989–1002. PMID 33567185

15. Garvey WT et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083–2091. PMID 36216945

16. Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 389:2221–2232. PMID 37952131

17. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 387:205–216. PMID 35658024

18. Nauck MA et al. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease. Diabetes Obes Metab 23(Suppl 3):5–29. PMID 34310013

19. Wilding JHH et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24(8):1553–1564. PMID 35441470

20. Rubino D et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 325(14):1414–1425. PMID 33755728

21. Park JS et al. (2024). GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science 385(6707):438–446. PMID 38935778

22. Alhadeff AL et al. (2012). GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153(2):647–658. doi:10.1210/en.2011-1808; Dossat AM et al. (2011). Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake. J Neurosci 31(42):14915–14922. doi:10.1523/JNEUROSCI.3262-11.2011

23. Volkow ND & Xu R (2025). GLP-1R agonist medications for addiction treatment. Addiction 120(2):198–200. PMID 39049203

24. Martinelli S et al. (2024). Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug Alcohol Depend 264:112424. PMID 39288591

25. Leggio L et al. (2023). GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med 29(12):2993–2995. PMID 38001271

It’s nearly midnight in Karlsruhe Germany, 1909. In a cramped, ill-lit laboratory, chemist Fritz Haber wipes sweat from his brow and watches a gleaming droplet condense inside his jury-rigged high-pressure reactor. He’s been at this for days, mixing air and hydrogen, tinkering with catalyst recipes, risking explosion with every attempt. And suddenly, against a century of failed hopes, there it is. One tiny bead of ammonia, a simple molecule, but the key to feeding a hungry world¹.

2. Introduction: The Most Useful Molecule You Never Think About

What is ammonia? For most of us, it’s the tangy smell in glass cleaner or the harsh reek from an old mop bucket. Chemically, ammonia (NH₃) is just three hydrogens and a lone nitrogen, a humble cluster of atoms, invisible yet essential for life itself.

Every leaf, loaf of bread, and living being depends on nitrogen. Plants crave it to make proteins; animals crave plants. But atmospheric nitrogen, which makes up 78% of the air, is locked away as triple-bonded N₂ gas, nearly impossible for living things to use². Before 1910, the world’s farms ran on guano (bat droppings), Chilean saltpeter, and the errant bolt of lightning—each one a rare, almost miraculous source of plant-friendly nitrogen.

Yet, by the dawn of the 20th century, the world faced a slow-motion catastrophe: the Great Nitrate Crisis. Populations were booming, soils were hungry, and old supplies were running out. Some projected imminent mass famine, as growth outstripped nature’s ability to feed us³.

3. The Nitrogen Dilemma

Nitrogen is both generous and stingy, everywhere but inaccessible. Only a few living organisms (notably certain bacteria) could snatch it from the air and “fix” it into forms plants could eat. Everyone else? They scoured the earth for guano islands, nitrate mines, or, in wartime, desperate chemical tricks.

In the mid-1800s, imperial powers sent navies and laborers to harvest Andean guano hills, fueling both bread baskets and battlefields. Even empires risked war for bags of poop ⁠—a fact almost too absurd for fiction. But by 1900, these sources were failing. If no solution came, would human civilization hit its fundamental ceiling?

4. Lighting the Spark: How Haber and Bosch Conquered Air

Fritz Haber was obsessed. For years, chemists had battered their heads against the puzzle of nitrogen, coaxing it, bombarding it, but always falling short. Haber, fueled by doggedness and ego, tried something new: combine air (nitrogen) and hydrogen under enormous pressure and heat, then pass it all over a metal catalyst (at first, rare osmium; soon, abundant iron worked almost as well). If luck held, NH₃—ammonia—would form⁴.

That June night in 1909, as he and his assistant watched ammonia droplets form, they realized they’d cracked the code. But making a few milliliters in a lab was a far cry from feeding nations.

That’s where Carl Bosch came in—a chemical engineer with a mind for machinery and a faith in the possible. Bosch’s challenge: scale up Haber’s delicate trick to a roaring factory, able to withstand steel-bending pressures and channel rivers of gas. After bruising setbacks (valves melted, alloys failed, entire plants stalled), the joint Basf (Badische Anilin- und Sodafabrik) team triumphed. In 1913, the first Haber-Bosch plant in Oppau, Germany, began turning literal air into gold—pouring out ammonia by the ton⁵.

5. From Air to Bread: A New World Unfolds

Ammonia itself is pungent and unlovely, but in the right hands it’s magic. Just add oxygen, and it becomes nitrate—the backbone of commercial fertilizer.

With synthetic ammonia, farmers everywhere could break free of the ancient chains: no need for guano, no Chilean mines. Fields bloomed with abundance. Wheat stalks grew lush and thick, rice paddies yielded bumper harvests, and the grip of famine began to loosen.

The numbers stagger. Today, over half the people alive are fed by crops grown with Haber-Bosch fertilizer⁶. If you pulled the ammonia plug, half the world would go hungry.

This molecular wizardry changed everything—from diets to demographics, geopolitics to the arc of everyday life. Humanity roared forward, fueled by a molecule once beyond its grasp.

6. Bombs and Backlashes: The Double-Edged Sword

But no magic comes without shadows. In World War I, Germany’s British blockade threatened to starve its explosives factories of nitrate. Enter Haber-Bosch: not only did it feed crops, it kept munitions lines banging out shells. Although perhaps grim, ammonia’s legacy is both loaf and bullet.

As the Green Revolution unfolded, another, subtler crisis loomed. Synthetic fertilizer runoff seeped into rivers, fueling algae blooms and creating “dead zones” in oceans where nothing larger than bacteria could survive⁷. The altered nitrogen cycle brought richer harvests—at the price of destabilized climates and poisoned waterways.

Humanity became addicted. Today, over 170 million metric tons of ammonia cascade through global agriculture, chemical plants, and fuel systems every year⁸. Even as we confront climate change, rising populations, and fractured ecosystems, we cannot turn away.

7. Quirks and Curiosities: Did You Know?

• The “Bread from Air” Miracle: When Haber’s process debuted, German newspapers swooned over the concept of “Brot aus Luft”—bread conjured from thin air⁹.

• Unintended Consequences: Fritz Haber, hailed for feeding billions, also pioneered chemical warfare—developing chlorine gas for the trenches.

• Ammonia in Space: NH₃ isn’t just a terrestrial player; vast lakes of it swirl on Jupiter and Saturn. On Saturn’s moon Titan, ammonia may help shape extraterrestrial chemistry10.

• Haber’s Dilemma: Awarded the Nobel Prize in Chemistry (1918) for “synthesizing bread from air,” Haber’s legacy remains fraught—a hero to some, a villain to others.

8. Today’s Reckoning: Can We Green the Miracle?

As the 21st century unfurls, the very tools that saved billions now threaten to undermine us. Ammonia factories consume immense energy, much from fossil fuels; fertilizer overuse grinds down soils and surges into waterways. The nitrogen cycle, once a slow dance, now stampedes.

Yet, hope stirs. Scientists race to engineer “green ammonia” using wind- or solar-powered electrolysis, striving to sever ammonia’s dependency on natural gas. Others engineer crops that host their own nitrogen-fixing bacteria, hinting at a future where fields fertilize themselves¹¹.

The question now: can we keep the bounty without courting disaster? Or, as with all great inventions, does every solution simply “kick the can” down the road?

9. Conclusion: The Fate of a Molecule, The Shape of Tomorrow

From Andean guano fields to the echo of ammonia reactors, humanity’s fate remains entwined with the chemistry of nitrogen. The Haber-Bosch process did more than unlock bread from air—it unshackled a limitation on civilization, for better and for worse.

Will we invent a new balance, or will Haber’s boon cost us yet? The story of ammonia is far from over—a flicker at the edge of discovery, history, and the world to come.

10. For Further Reading

1. The Alchemy of Air by Thomas Hager (Amazon link)

2. Enriching the Earth by Vaclav Smil (Publisher link)

3. National Geographic: Why Ammonia Is the Most Important Industrial Chemical

4. Nature: The Haber–Bosch Reaction: the Engine of the Modern World

5. Smithsonian: Fritz Haber's Dark Genius

Sources

1. Hager, T. (2008). The Alchemy of Air.

2. Smil, V. (2001). Enriching the Earth.

3. Erisman, J.W. et al. (2008). How a century of ammonia synthesis changed the world. Nature Geo 1, 636–639.

4. Wikipedia: Haber Process.

5. National Geographic: Ammonia.

6. Environmental Research Letters, 2013: The role of ammonia in food security.

7. EPA: Nutrient Pollution - Effects.

8. IEA: Ammonia Technology Roadmap.

9. Science History Institute: Fritz Haber.

10. NASA: Ammonia in space.

11. Nature News: ‘Green’ ammonia team.

For two long, cold seasons, they set the data aside. But when the new instrument arrived and confirmed the terrifying readings of the old one, a chilling realization washed over the team. The instrument wasn't broken. The sky was.

Our planet wears an invisible guardian. High in the stratosphere, some 10 to 30 miles above our heads, floats a delicate concentration of molecules called ozone. Each ozone molecule is a simple trio of oxygen atoms (O₃), bound together in a shape that makes it a master at absorbing the sun’s most aggressive ultraviolet rays, specifically UV-B radiation. This planetary sunscreen is the only reason life as we know it can exist on Earth’s surface. Without it, the sun’s energy would scorch the continents, sterilize the seas, and cause catastrophic rates of skin cancer and cataracts in animals and humans.

We owe our lives to this thin veil of gas. And in the 1980s, we discovered we were systematically destroying it.

Subscribe now

The Chemical Detectives

The first whisper of trouble came more than a decade earlier, in a quiet university lab in California. It was 1974, and two chemists, Mario Molina and F. Sherwood “Sherry” Rowland, were investigating a class of popular industrial chemicals: chlorofluorocarbons, or CFCs.

You may know them by their trade name, Freon. In the mid-20th century, CFCs were considered miracle molecules. They were non-toxic, non-flammable, and incredibly stable—perfect as refrigerants in air conditioners, propellants in aerosol cans, and agents for blowing foam insulation. They seemed utterly harmless. But Rowland and Molina’s calculations told a different, more sinister story.²

Their hypothesis was as elegant as it was alarming. Because CFCs were so stable, they didn’t break down in the lower atmosphere. Instead, they lingered, and over decades, they drifted slowly upward into the stratosphere. Once there, exposed to the fierce, unfiltered ultraviolet light of the sun, the CFC molecules were finally shattered. This act of destruction released their chemical assassins: chlorine atoms.

A single chlorine atom, they predicted, could act as a catalyst in a long, patient demolition of the ozone layer. It would steal an oxygen atom from an ozone molecule, breaking it. Then, through another reaction, it would release that oxygen and be free to seek out another ozone molecule, and another, and another. They calculated that one chlorine atom could destroy up to 100,000 ozone molecules before it was finally neutralized.³ It was like a tiny, chemical Pac-Man, endlessly munching through our planetary shield.

When they published their findings, the work was met with skepticism and fierce resistance from the chemical industry. Could a simple, inert chemical used in refrigerators and hairspray really be unraveling the sky? For years, their theory remained just that—a dire, unproven warning

.

A Hole at the Bottom of the World

Then came Halley Bay.

When the British team finally published their data in the journal Nature in 1985, the scientific community was stunned.⁴ The “ozone hole,” as the media quickly dubbed it, wasn’t a literal hole but a region of catastrophic seasonal depletion. And it was centered over the one place on Earth where the chemical demolition was happening with terrifying efficiency: Antarctica.

Scientists soon pieced together why. During the deep, dark Antarctic winter, a swirling vortex of winds traps a mass of super-chilled air over the continent. In this frigid environment, wispy, iridescent clouds form high in the stratosphere. These Polar Stratospheric Clouds, beautiful to behold, provided a perfect microscopic surface for chlorine chemistry to run wild. All winter long, inert chlorine compounds collected on these ice crystals. When the sun finally returned in the spring, its light triggered the chemical reactions that unleashed the chlorine atoms all at once.

The Antarctic ozone hole was the smoking gun. It proved Rowland and Molina’s hypothesis with terrifying clarity. The public was galvanized by images of a gaping wound in our atmosphere. The sky, it seemed, was indeed falling.

A Treaty to Heal the World

What happened next is perhaps the most remarkable part of the story. Faced with an undeniable existential threat, the world acted. Science, industry, and policy makers mobilized with a speed and unity that remains stunning to this day.

In 1987, just two years after the hole was confirmed, 46 countries gathered to sign the Montreal Protocol on Substances that Deplete the Ozone Layer. It wasn’t a vague promise; it was a binding, ambitious global treaty to phase out the production and use of CFCs and other ozone-destroying chemicals.

The Montreal Protocol succeeded where so many other international efforts fail for a few key reasons. It was decisive, setting clear, legally-binding targets. It was fair, creating a fund to help developing nations transition to safer alternatives. And most importantly, it was adaptable. It was designed as a “start and strengthen” agreement, allowing its restrictions to be tightened as more scientific evidence became available, which it was, multiple times.⁵ It stands today as the only UN treaty in history to be ratified by every single country on Earth.

Did You Know? The Scent of a Storm

Long before we understood its chemistry, humans knew ozone by its smell. The word ozone comes from the Greek ozein, meaning “to smell.” It’s the sharp, clean, strangely metallic scent you can sometimes detect in the air after a powerful thunderstorm. That smell is ozone being created by the immense electrical energy of a lightning strike, which splits atmospheric oxygen molecules (O₂) apart, allowing them to reform as O₃. For a time in the late 19th century, before its true nature was known, this “scent of lightning” was even thought to be a healthy, purifying substance.

The Long Mend

The Montreal Protocol worked. Almost immediately, the amount of chlorine being pumped into the atmosphere began to fall. But the sky is a patient patient. The CFCs already up there would take decades to dissipate, and the healing would be a slow, generational process.

Today, we can see the results. According to the latest assessments from NASA and the United Nations, the ozone layer is steadily recovering.⁶ The hole over Antarctica still forms each spring, but it is smaller and less severe than it was at its peak in 2000. Projections show that the ozone layer over the mid-latitudes should recover to 1980 levels by around 2040. The stubborn Antarctic hole is expected to be fully closed by 2066.

The story continues to evolve. In 2016, the protocol was updated with the Kigali Amendment. This update targets hydrofluorocarbons (HFCs), the chemicals developed to replace CFCs. While safe for the ozone layer, HFCs were discovered to be potent greenhouse gases, thousands of times more powerful than carbon dioxide. By phasing them down, the Montreal Protocol is now also one of our most effective tools in the fight against climate change.⁷

A Blueprint for Hope

The rescue of the ozone layer is more than a triumphant chapter in environmental history. It is a blueprint for hope. It is a shining example of what humanity can achieve when faced with a global crisis. It proves that when scientific warnings are heeded, when nations are willing to cooperate, and when industry is spurred to innovate, we are capable of solving even the most daunting environmental challenges.

In an era dominated by the seemingly intractable problem of climate change, the story of the ozone hole serves as a powerful reminder. We have healed the sky once before. We can do it again.

Bibliography & For Further Reading

1. Farman, J. C., Gardiner, B. G., & Shanklin, J. D. (1985). Large losses of total ozone in Antarctica reveal seasonal ClOx/NOx interaction. Nature, 315(6016), 207-210.

2. Molina, M. J., & Rowland, F. S. (1974). Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature, 249(5460), 810-812.

3. NASA Ozone Watch. "Ozone Basics." https://ozonewatch.gsfc.nasa.gov/facts/basics_en.html

4. Solomon, S. (1990). Progress towards a quantitative understanding of Antarctic ozone depletion. Nature, 347(6291), 347-354.

5. United Nations Environment Programme. "About the Montreal Protocol." https://www.unep.org/ozonaction/who-we-are/about-montreal-protocol

6. World Meteorological Organization (WMO). (2022). Scientific Assessment of Ozone Depletion: 2022.

7. United Nations Environment Programme. "Kigali Amendment." https://www.unep.org/ozonaction/kigali-amendment

On Friday, April 16th, 1943, the Swiss chemist Dr. Albert Hofmann was working in his laboratory at Sandoz Pharmaceuticals in Basel. He was a meticulous man, a scientist dedicated to deconstructing the chemical secrets of medicinal plants. But that afternoon, he was pulled by what he would later call a “peculiar presentiment” toward a compound he had first synthesized and then shelved five years earlier. Its name was lysergic acid diethylamide-25. LSD.¹

He re-synthesized a small amount. As he worked, a peculiar dizziness overcame him. He went home to lie down, and there, with his eyes closed, he was visited by “an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.”¹ It was a wondrous, if unsettling, two hours. He suspected he must have absorbed a trace amount of the substance through his fingertips.

But how much? And what, exactly, had he stumbled upon? The only way to find out was to conduct an experiment. On himself.

Three days later, he would take a bicycle ride that would change the course of neuroscience forever.

The Alchemist’s Fateful Ride

To call ergot a fungus is an understatement. For centuries, it was a medieval terror. A parasitic growth on rye grain, it was responsible for a horrifying affliction known as St. Anthony’s Fire, which caused burning sensations in the limbs, gangrene, and terrifying hallucinations.² Yet within this dark fungus, Hofmann believed there lay useful medicine. He was searching for a circulatory stimulant, a molecule to help with blood flow. In 1938, the 25th compound he derived in this series—LSD-25—had shown little promise in animal tests and was put away.

Now, on April 19th, 1943, he was sure it held a different kind of power.

Based on similar compounds, he decided a dose of 250 micrograms—a quarter of a milligram, a speck of matter barely visible to the naked eye—would be a safe, threshold amount. At 4:20 PM, he dissolved it in water and drank it. For nearly an hour, nothing. And then, as he noted in his lab journal, the world began to tilt. Dizziness. Anxiety. Visual distortions. Laughter.¹

The bicycle ride home, taken with his lab assistant, became a journey into another dimension. The familiar Basel streets rippled and warped. The ground seemed to breathe beneath his wheels. A neighbor who offered him milk appeared not as a kind woman, but as a “malevolent, insidious witch with a colored mask.”¹ Back at home, the terror mounted. He feared he was losing his mind, that his own molecule was poisoning him. He called for a doctor. But as the physician found no physical abnormalities, a new feeling began to creep in. The terror subsided, and in its place came a profound sense of wonder. The patterns on the floor pulsed with life. The closed-eye hallucinations returned, this time not as a chaotic stream, but as magnificent, unfolding visions.

Albert Hofmann had just taken the world’s first acid trip. He was the first human to see what this molecule could do. But the next eighty years would be spent trying to understand how it did it.

A Master Key for the Mind’s Lock

What on Earth was happening inside Hofmann’s brain? How could a substance measured in millionths of a gram so completely overhaul the nature of reality?

The answer lies in an act of molecular mimicry.

Your brain runs on a constant conversation between neurons, mediated by chemicals called neurotransmitters. One of the most important is serotonin, a molecule that governs nearly everything: your mood, your sleep, your appetite, and crucially, your perception of the world. It’s the brain’s great manager.

When Hofmann created LSD, he unknowingly sculpted a near-perfect imitation of serotonin. It is a molecular master key, shaped so exquisitely that it can slide into the locks meant for serotonin—specialized proteins on the surface of neurons called receptors.

LSD’s primary target is a very specific lock: the 5-HT2A receptor.³ When this receptor is activated, it changes the way neurons fire and communicate. But LSD doesn’t just fit the lock; it gets stuck. Recent research using cryo-electron microscopy has revealed LSD’s stunning trick: when the molecule slides into the 5-HT2A receptor, a flexible loop of the protein folds over it like a lid, trapping it there for hours.⁴

This “lid-latch” mechanism explains LSD’s incredible potency and long duration. A tiny amount of the molecule can cause a huge and lasting effect because once it’s in, it’s not leaving anytime soon. It’s not just knocking on the door; it’s picking the lock and settling in for the night.

The Symphony of a Dissolving Self

If locking into a single receptor is the cause, what is the effect on the brain as a whole? Imagine your brain’s activity is an orchestra. Day to day, there’s a conductor on the podium, keeping everyone in time, making sure the violins don’t overpower the woodwinds. This conductor is a network of brain regions called the Default Mode Network (DMN).

The DMN is the seat of your ego. It’s the part of you that ruminates about the past, worries about the future, and maintains a stable sense of “I.” It’s the voice in your head.⁵

Modern fMRI scans of brains on LSD show something remarkable: the DMN goes quiet. The conductor leaves the stage.⁶

With the conductor gone, the orchestra begins to improvise. Brain regions that rarely speak to each other suddenly strike up vibrant conversations. The visual cortex starts chattering with the part of the brain responsible for self-awareness. The auditory centers link up with emotional processing hubs. The rigid, segregated structure of the brain dissolves into a more unified, interconnected, and flexible state—a state neuroscientists call a higher “entropy” brain.⁶

This is the neural basis for the psychedelic experience: the "dissolving" of the ego, the blending of senses (seeing sounds, hearing colors), and the profound feeling of being connected to everything. It’s not just chaos; it’s a new kind of harmony.

A Pinprick of Power

It’s difficult to overstate LSD’s potency. An active dose is around 100 micrograms (0.0001 grams). If you took a single packet of sugar (about one gram) and divided it into 10,000 equal piles, just one of those tiny piles would be enough for a standard dose. It is thousands of times more potent by weight than psilocybin (from magic mushrooms) or mescaline (from peyote), making its synthesis in 1938 a truly unique chemical achievement.

From Problem Child to Prodigal Son

Albert Hofmann lived to be 102. He watched his “problem child” escape the lab and ignite a cultural revolution, become a catalyst for both artistic genius and psychological breakdown, and ultimately be outlawed and driven underground. He always maintained that if used responsibly, LSD was a “medicine for the soul.”

Today, science is catching up to Hofmann’s intuition. The very effects that made LSD a cultural threat—the dissolution of the ego and the radical shift in perspective—are now being explored as powerful therapeutic tools. In carefully controlled clinical settings, psychedelic-assisted therapy is showing remarkable promise in FDA-approved trials for treating end-of-life anxiety, PTSD, and severe depression.⁷

The journey that began with a strange feeling and a bicycle ride in Basel is far from over. The molecule born from a medieval fungus has become a key, not just for unlocking altered states, but for understanding the very nature of consciousness itself. It seems Hofmann’s problem child may finally be coming home.

Did You Know?

• Before it was a counter-culture icon, the CIA saw LSD as a tool. In the infamous MKUltra project, they tested the drug on citizens, hoping to develop it as a truth serum or mind-control agent.

• The word “psychedelic” was born from a poetic exchange. In 1956, psychiatrist Humphry Osmond wrote to author Aldous Huxley, struggling for a word to describe these drugs. Huxley shot back the winning reply: “To fathom Hell or soar angelic, just take a pinch of psychedelic.” The term means “mind-manifesting.”

• Psychedelic therapy isn’t new. In the 1950s and 60s, thousands of patients were legally treated with LSD for conditions like alcoholism, with some studies showing remarkable success before research was shut down in the late 60s.

• It inspired the pioneers of personal computing. Apple co-founder Steve Jobs called his experience with LSD “one of the most important things in my life,” believing it opened his mind to the kind of innovative thinking that led to the Macintosh.

Explore the Intersection of Molecules & Morals

This story is only the first entry in our ongoing series, Molecules & Morals, where we unlock the stories of the world's most controversial substances. From the poppy that fueled empires to the synthetic powders that redefined warfare, we'll explore the potent chemistry that has shaped our history and our minds.

For Further Reading

1. LSD: My Problem Child by Albert Hofmann — The definitive, first-hand account of the discovery and the chemist’s lifelong relationship with his creation. (Link is to a free PDF hosted by MAPS).

2. How to Change Your Mind by Michael Pollan — An accessible and beautifully written exploration of the new science of psychedelics, from LSD to psilocybin.

3. “The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs” by Carhart-Harris et al. (Frontiers in Human Neuroscience) — For those wanting a deeper scientific dive into the brain imaging studies.

Bibliography

¹ Hofmann, A. (1980). LSD: My Problem Child. McGraw-Hill.
² Eadie, M. J. (2009). Convulsive ergotism: epidemics of the story of St Anthony's fire. The Lancet Neurology, 8(1), 86-92.
³ Nichols, D. E. (2016). Psychedelics. Pharmacological reviews, 68(2), 264-355.
⁴ Wacker, D., et al. (2017). Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell, 168(3), 377-389.e12.
⁵ Raichle, M. E. (2015). The brain's default mode network. Annual review of neuroscience, 38, 433-447.
⁶ Carhart-Harris, R. L., et al. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853-4858.
⁷ Gasser, P., et al. (2014). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology, 28(12), 1125-1135.

Until now. A landmark study published in Nature by Emerson-King et al. reports the creation of a molecule that shatters previous records, holding its magnetic state steady at a remarkable 100 Kelvin (−173°C / −280°F).¹ This is more than just an incremental improvement. It is a monumental step toward making molecular-scale technologies a practical reality.

Did You Know?

• Data Storage smaller than a Pinhead: If we could build a hard drive using SMMs, you could theoretically store the entire content of every book in the Library of Congress on a device the something like the size of a postage stamp.

• Beyond 1s and 0s: Unlike a classic computer bit that is either a 1 or a 0, the quantum state of an SMM can be both at the same time. This property makes them a leading candidate for building the "qubits" needed for quantum computers.

• A Magnet of One: A fridge magnet works because trillions of atoms align their magnetic fields. A single-molecule magnet is fundamentally different. In an SMM, the entire molecule acts as one cohesive unit and becomes a tiny, perfect magnet.

  

Breaking the 100 K Barrier

The "blocking temperature" is the all-important number for an SMM. Below this temperature, it can hold magnetic information; above it, its memory is lost by thermal energy. The previous record, set in 2017, was an impressive 60 K.² This new molecule, a cleverly designed dysprosocenium (or “sandwich”) complex, doesn't just beat that record. It soars past it to reach 100 K.

Why is this so important? Because 100 K is warmer than liquid nitrogen (77 K). This means any future device using these molecules could be cooled with cheap, abundant liquid nitrogen instead of extremely expensive and increasingly scarce liquid helium. It’s the difference between a niche laboratory curiosity and a technology that could be built and used around the world.

A Perfect Molecular Cage Is the Secret to Its Success

So, how did the researchers achieve this? They essentially built a molecular fortress. The central dysprosium atom, which provides the magnetic muscle, is protected by a perfectly symmetrical "cage" of other atoms. This rigid structure shields the magnet from outside vibrations and prevents its magnetic state from spontaneously flipping through a phenomenon known as quantum tunneling.

By creating this near-perfect molecular environment, the team built a magnet that is incredibly resistant to losing its information, allowing it to function at a temperature once thought impossible for a single molecule.¹

What This Means for the Future

While there are still hurdles to overcome, such as arranging these molecules on a surface and reading their states reliably, this discovery makes the path forward much clearer. It proves that the fundamental physics allows for robust molecular magnets and gives scientists a blueprint for creating even better ones.

The road ahead involves refining these molecules, exploring ways to mass-produce them, and engineering the hardware that can interface with them. But the most significant barrier, the temperature wall, has now been dramatically pushed back.

Outlook

The work by Emerson-King and colleagues has redefined the limits of what's possible in molecular magnetism. By creating a single molecule that acts as a magnet at 100 K, they have laid the foundation for a new generation of technology. The age of practical molecular magnets is seemingly no longer a distant dream; it's a milestone we can now see on the horizon.

References

1. Emerson-King, J., Gransbury, G.K., Atkinson, B.E. et al. Soft magnetic hysteresis in a dysprosium amide–alkene complex up to 100 kelvin. Nature 643, 125–129 (2025). https://doi.org/10.1038/s41586-025-09138-0

2. Goodwin, C. A. P., Ortu, F., Reta, D., Chilton, N. F., & Mills, D. P. (2017). Molecular magnetic hysteresis at 60 kelvin in dysprosocenium. Nature, 548, 439–442.

3. Leuenberger, M. N., & Loss, D. (2001). Quantum computing in molecular magnets. Science, 294, 2088–2090.

Cholesterol is one of the most talked-about molecules in health and nutrition, yet it’s often misunderstood. While many people associate cholesterol with heart disease and dietary warnings, this essential lipid plays a crucial role in every cell of your body. Understanding what cholesterol is, how it functions, and its impact on your health can help you make informed choices about your diet and lifestyle.

Unlike many other molecules in the body that quietly perform their functions, cholesterol has become a central figure in both scientific research and public debate. Its importance—and the controversies surrounding it—make cholesterol a molecule everyone should understand.

What Is Cholesterol?

Cholesterol is a type of lipid molecule found in every cell of the human body. With a molecular weight of 386.65 g/mol¹, this fat-like substance is essential for life. But what is cholesterol, really? It’s a building block for cell membranes, a precursor for vital hormones, and a key player in the production of vitamin D.

The History of Cholesterol: From Discovery to Debate

The history of cholesterol begins in the 18th century, when French chemist François Poulletier de la Salle first isolated it from gallstones. For decades, cholesterol was simply a scientific curiosity. But in the 20th century, researchers discovered a link between cholesterol and heart disease, and cholesterol quickly became a household word—often for the wrong reasons.

Cholesterol in Health: Friend or Foe?

Cholesterol in health is a story of balance. Your body needs cholesterol to:

• Build and maintain cell membranes

• Produce hormones like estrogen, testosterone, and cortisol

• Synthesize vitamin D from sunlight

• Support brain health (approximately 20–25% of the body’s cholesterol is found in the brain, mostly in myelin²)

But too much cholesterol, especially low-density lipoprotein (LDL, or “bad” cholesterol), can lead to plaque buildup in arteries and increase the risk of heart disease. High-density lipoprotein (HDL, or “good” cholesterol) helps remove excess cholesterol from the bloodstream, reducing this risk³.

Cholesterol in Food: What You Need to Know

Cholesterol in food has long been misunderstood. While foods like eggs, cheese, and meat contain cholesterol, most of the cholesterol in your body is actually made by your liver and intestines—about 80%⁴. Only about 20% comes from the foods you eat. For most people, dietary cholesterol has only a modest impact on blood cholesterol levels. Instead, saturated and trans fats in food have a much greater effect on raising LDL cholesterol.

Cholesterol Facts: Surprising Truths

• Cholesterol is essential for life: Every cell in your body needs cholesterol to function.

• Your liver makes most of your cholesterol: About 80% is produced internally; only a small portion comes from food⁴.

• Cholesterol is the precursor to vitamin D: Sunlight helps your body turn cholesterol into this vital nutrient.

• Cholesterol is vital for brain health: The brain contains about 20–25% of the body’s cholesterol².

• The “cholesterol myth” is evolving: Recent studies show that for most people, dietary cholesterol has a limited effect on blood cholesterol.

The Impact Today: Cholesterol and Heart Disease

Cholesterol’s impact on modern health is profound. Cholesterol and heart disease remain a major focus of medical research and public health. Between 2017 and 2020, 10% of adults age 20 or older in the United States had total cholesterol levels above 240 mg/dL⁵. Abnormal levels of cholesterol are associated with a significantly increased risk of cardiovascular disease (CVD) mortality⁶. Statins and other cholesterol-lowering drugs have saved millions of lives, but the conversation about diet, genetics, and the true role of cholesterol in heart disease continues to evolve.

Did You Know? (Cholesterol Quick Facts)

• Cholesterol is not inherently “bad”: It’s essential for hormone production and cell structure.

• HDL and LDL are not cholesterol themselves: They are lipoproteins that transport cholesterol in the blood.

• Eggs are back on the menu: For most people, eating eggs does not significantly raise blood cholesterol.

• Cholesterol is found only in animal products: Plants do not contain cholesterol.

• Cholesterol is crucial for digestion: It helps your body make bile acids, which digest fats.

• Want to explore the structure in 3d yourself? Try here!

Curious for more? Subscribe to MolecularWeights and discover the hidden stories behind the molecules that shape our world, one fascinating fact at a time. Have a question about cholesterol or another molecule? Leave a comment below!

Bibliography

1. Cholesterol | C27H46O | CID 5997 - PubChem.
   https://pubchem.ncbi.nlm.nih.gov/compound/Cholesterol

2. Brain Cholesterol: Long Secret Life Behind a Barrier.
   Björkhem, I. (2004). Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), 806–815.
   https://www.ahajournals.org/doi/full/10.1161/01.atv.0000120374.59826.1b

3. High Cholesterol Facts | Cholesterol | CDC.
   https://www.cdc.gov/cholesterol/data-research/facts-stats/index.html

4. How it's made: Cholesterol production in your body - Harvard Health.
   https://www.health.harvard.edu/heart-health/how-its-made-cholesterol-production-in-your-body

5. High Cholesterol Facts | Cholesterol | CDC.
   https://www.cdc.gov/cholesterol/data-research/facts-stats/index.html

6. Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies.
   Jung, E. (2022). International Journal of Environmental Research and Public Health, 19(14), 8272.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC9316578/

There are biomolecules that build, and biomolecules that break. But some, like DNA polymerase, are the quiet scribes of existence—copying, correcting, and preserving the code that makes us who we are.

Imagine a cell, humming with functional purpose. Deep inside, a double helix unwinds, its rungs splitting apart like the pages of a well-loved book. Enter DNA polymerase: a tiny, tireless enzyme, gliding along the strands, reading each letter, and matching it with its perfect pair. It works with astonishing speed and precision, copying billions of letters in the time it takes you to blink. Every cell division, every new leaf, every growing child owes its existence to this molecular copyist.

But DNA polymerase is more than a biological workhorse. It is the reason life can persist, adapt, and evolve. When mistakes slip through—rare, but inevitable—they become the raw material for evolution, the subtle edits that drive the story of life forward.

In the 20th century, scientists harnessed the power of DNA polymerase for their own ends. The invention of the polymerase chain reaction (PCR) turned this humble enzyme into a superstar, able to copy a single strand of DNA into millions in just a few hours. Suddenly, the secrets of genes, ancestry, and disease were within reach. Forensic science, medical diagnostics, and even the mapping of the human genome—all became possible thanks to the relentless fidelity of DNA polymerase.

So next time you marvel at the diversity of life, the power of modern medicine, or the mysteries hidden in your own DNA, remember the enzyme at the heart of it all: the copyist, the corrector, the quiet artist of the cell.

The Impact Today

DNA polymerase is the engine behind every living thing’s ability to grow, heal, and reproduce. In the lab, it’s the backbone of genetic testing, ancestry kits, and the fight against disease. PCR tests—powered by a heat-loving version of DNA polymerase—helped track and diagnose COVID-19, and continue to revolutionize everything from agriculture to criminal justice.

As we enter the age of personalized medicine and synthetic biology, DNA polymerase remains at the center of the story—proof that even the smallest machines can have the greatest impact.

Did You Know?

• DNA polymerase can add up to 1,000 DNA bases per second in bacteria, and about 50 per second in human cells.

• The discovery of “Taq polymerase”—a heat-resistant DNA polymerase from a Yellowstone hot spring microbe—made PCR practical and launched the biotech revolution.

• DNA polymerase has a built-in “proofreading” function, catching and correcting most mistakes as it copies DNA.

• Without DNA polymerase, life as we know it would be impossible: no growth, no healing, no inheritance.

Curious for more? Please consider subscribing to Molecular Weights and discover the hidden stories behind the molecules that shape our world.

File image below, pdf attached.

Elephant Toothpaste

1.48MB ∙ PDF file

Download

Download

Subscribe now

Caffeine’s Molecular Weight: 194.19 g/mol

There’s a moment, just before dawn, when our world is quiet and the first rays of sunlight slip through the window. For millions, this is the moment of ritual: the kettle whistles, the coffee maker gurgles, the aroma of roasted beans or steeped leaves fills the air. In that cup, whether it’s coffee, tea, or something more exotic, lies a molecule that has shaped empires, sparked revolutions, and fueled countless mornings—caffeine.

Caffeine’s story begins in the tangled roots and glossy leaves of plants scattered across the globe. Ancient Chinese emperors sipped tea for clarity of mind. Ethiopian goatherds noticed their flock’s newfound energy after nibbling mysterious red berries. In the Middle East, coffeehouses became centers of conversation, debate, and sometimes sedition—so much so that rulers tried (and failed) to ban the drink.

What is it about caffeine that makes it so irresistible? On a molecular level, it’s a master of disguise, slipping into the brain and blocking the signals that tell us we’re tired. The result: alertness, focus, and a gentle nudge to keep going, whether you’re writing a novel, studying for finals, or just trying to make it through a Monday.

But caffeine is more than just a pick-me-up. It’s a social glue, a reason to gather, a spark for creativity and connection. From the bustling cafés of Paris to the quiet tea ceremonies of Kyoto, caffeine has woven itself into the fabric of our daily lives.

So the next time you cradle that warm mug, remember: you’re not just drinking a beverage. You’re partaking in a centuries-old tradition, powered by a molecule that has helped shape the world, one cup at a time.

The Impact Today

Caffeine is the world’s most widely consumed psychoactive substance. It’s in our coffee, tea, chocolate, sodas, and energy drinks. For many, it’s a daily necessity—a way to jumpstart the morning or push through the afternoon slump. Entire industries, from tech startups to university libraries, run on the collective buzz of caffeine.

But our relationship with caffeine is evolving. As we learn more about its effects on sleep, anxiety, and health, people are experimenting with new ways to enjoy it—think cold brew, matcha lattes, or even caffeine-infused gum. Meanwhile, scientists are studying caffeine’s potential benefits, from improved memory to protection against certain diseases.

Still, moderation is key. Too much caffeine can lead to jitters, insomnia, and a racing heart. Like all powerful molecules, it demands respect—and a little self-awareness.

Did You Know?

• Caffeine works by blocking adenosine, a neurotransmitter that makes you feel sleepy. That’s why you feel more alert after your morning cup.

• Coffee was once considered so dangerous that it was banned in Mecca, Constantinople, and even parts of Europe at various times in history.

• The Boston Tea Party wasn’t just about taxes—it helped shift American tastes from tea to coffee, making the U.S. a coffee-loving nation.

• Caffeine is found in over 60 plant species, including coffee beans, tea leaves, cacao pods, and even guarana berries.

• Decaf coffee isn’t completely caffeine-free: it usually contains about 2–5 mg of caffeine per cup.

• For more reading about caffeine here is a good resource.

• See caffeine for yourself!

Curious for more? Subscribe to Molecular Weights and discover the hidden stories behind the molecules that shape our world.

Penicillin Family Molecular Weight: 334–350 g/mol

Imagine this: You come back from vacation, your inbox overflowing, your desk a disaster. You sigh, roll up your sleeves, and start sorting through the chaos. Now, imagine that in the middle of all that mess, you stumble on something that will change the world forever.

That’s exactly what happened to Alexander Fleming in 1928. His lab was cluttered, his petri dishes stacked haphazardly, experiments left to fend for themselves. But in that mess, Fleming noticed something odd—a dish where bacteria had vanished, leaving a clear halo around a fuzzy patch of mold. Most of us would have tossed it out. Fleming leaned in and investigated.

What he found was penicillin, the world’s first true antibiotic. It didn’t just kill bacteria—it did so gently, leaving human cells unharmed. It was a game-changer, but at first, almost no one noticed. Years passed. The world spun on. But the story didn’t end there.

A team of scientists picked up where Fleming left off, turning that accidental discovery into a medicine that could be mass-produced. By World War II, penicillin was saving thousands of lives—soldiers, children, everyday people who would have died from infections we now treat with a simple pill.

Today, we take antibiotics for granted. But the next time you reach for that little bottle, remember: it all started with a messy lab, a curious mind, and a bit of mold that refused to be ignored.

Sometimes, the biggest breakthroughs come from the smallest, most unexpected places. All it takes is someone willing to look a little closer.

The Impact Today

Penicillin didn’t just change medicine—it changed the world. Before antibiotics, even a small cut or a sore throat could turn deadly. Today, thanks to penicillin and the antibiotics that followed, we routinely survive infections that once wiped out entire communities. Surgeries are safer, childbirth is less risky, and life expectancy has soared.

But the story isn’t over. The rise of antibiotic resistance is a growing threat, as bacteria evolve to outsmart our medicines. Scientists are racing to discover new antibiotics and develop smarter ways to use the ones we have. A lesson? The greatest discoveries need care, stewardship, and a willingness to keep looking to find the next breakthrough.

Did You Know?

• Penicillin was called a “miracle drug” during World War II, and its mass production was considered as important to the war effort as tanks and planes.

• Fleming warned about antibiotic resistance as early as 1945, predicting that misuse could make penicillin less effective—a warning we’re still grappling with today.

• The first patient treated with penicillin was a policeman with an infection. He improved dramatically, but supplies ran out before he could be fully cured, highlighting the urgent need for mass production.

• Penicillium notatum, the mold that started it all, was later replaced by a different species, Penicillium chrysogenum, which produced much more penicillin and made large-scale manufacturing possible.

• Further reading about the discovery of penicillin can be found here.

• Take a look at a penicillin drug yourself!

Curious about the impact of more molecules? Subscribe to Molecular Weights and discover the hidden stories behind the molecules that weigh heavy on our world our world.